Humira® Alternatives

Humira is a TNF-alpha inhibitor utilized to treat an extensive range of inflammatory conditions, including Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and Ulcerative colitis. However, Humira can suppress the immune system's ability to fight off infections caused by bacteria, fungi, or viruses, potentially increasing the risk of developing certain types of cancer.

Humira is FDA approved for the following indications: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Arthritis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis.

Tremfya, an interleukin inhibitor, is indicated for the treatment of plaque psoriasis or psoriatic arthritis in adults. Patients can learn to self-administer Tremfya subcutaneously every eight weeks, and the most common side effects are injection site reactions and an elevated risk of infection.

Tremfya is FDA approved for the following indications: Plaque Psoriasis and Psoriatic Arthritis.